Shift Pharmaceuticals - Crunchbase Company Profile & Funding

Overview

Shift Pharmaceuticals

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Shift Pharmaceuticals

CB Rank

425105

Shift Pharmaceuticals provides research and development of Antisense Oligonucleotides as a medicine for a variety of genetic disorders.

Founded

obfuscation

Private

Overland Park, Kansas, United States

1-10

www.shiftpharmaceuticals.com

Pharmaceutical

Product Research

Professional Services

Key People

Stephen O’Connor: CEO
Past Role: ImpeDx Diagnostics, Co-Founder and CEO

Details

Operating Status

Active

Company Type

For Profit

Phone Number

+1 6268932514

Predictions & Insights

Products & Services

E1v1.11

An antisense oligonucleotide compound designed to increase production of functional survival motor neuron protein by modifying SMN2 gene expression in spinal muscular atrophy patients.

SHC1A-012

An antisense oligonucleotide compound targeting PMP22 protein overproduction to treat Charcot Marie Tooth Syndrome type 1A by restoring myelin sheath integrity in peripheral nerves.